BCRX: External innovation and product diversification drive growth toward a $1B+ rare disease portfolio
The company is shifting from internal discovery to external innovation, aiming for three marketed products and over $1 billion in revenue by 2030. ORLADEYO continues to drive growth, with new pediatric indications and strong real-world evidence, while navenibart and pipeline assets expand the rare…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.